NCT06663605View on ClinicalTrials.gov

Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.

PHASE1CompletedINTERVENTIONAL

Enrollment

89

Participants

Timeline

Start Date

November 5, 2024

Primary Completion Date

July 7, 2025

Study Completion Date

August 7, 2025

Conditions

Ulcerative Colitis (UC)Healthy Volunteer

Interventions

DRUG

PALI-2108

Oral dose

DRUG

PALI-2108 Placebo

Oral dose

Trial Locations (1)

H3P3H5

Altasciences, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Altasciences Company Inc.

INDUSTRY

lead

Palisade Bio

INDUSTRY

NCT06663605 - Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. | Biotech Hunter | Biotech Hunter